Shadd Dales of The Dales Report asks InMed CEO, Eric A. Adams, about the recent news of InMed’s patent application for a cannabinoid treatment targeting neurodegenerative diseases like Alzheimer’s, Parkinson’s and Huntington’s.
—
Excerpt from The Dales Report.
“We’re continuing our pharmaceutical research and we’re looking at the application of these rare cannabinoids and treating a number of different diseases.”
Adams continues, “as you know, CBN is the first product that we brought forward in Epidermolysis Bullosa, a genetic skin condition that’s pretty rare. We’re also looking at glaucoma, that’s still preclinical, but we’re headed to the clinic, sometime in the next 12 to 16 months. So we’re headed in the right direction with those.”
“We’ve always known that the rare cannabinoids as a class of compounds, holds a lot of promise and a number of different areas.”
Adams and the team at InMed are fresh off of their acquisition of BayMedica, the U.S. brand specializing in the development and manufacturing of rare cannabinoids, and the conversation explores the exciting plans that InMed has for the future of cannabis in the health and wellness space.
“BayMedica is very well positioned as a manufacturer of rare cannabinoids for that space. And we think we can leverage off of their manufacturing know-how to launch new rare cannabinoids into the health and wellness space and help us down the road as we start to look at these pharmaceutical products.”
Read the full article in The Dales Report.
